ERBB2 and breast carcinoma: Another trial called AVIATOR is a phase 2 study recruiting 100 patients aiming to determine the recommended dose of utomilumab in combination with T-DM1 or trastuzumab in subjects with advanced HER2+ breast cancer (Table 1).